Page 21 - Read Online
P. 21

Page 6 of 8                              Gavard Molliard et al. Plast Aesthet Res 2018;5:17  I  http://dx.doi.org/10.20517/2347-9264.2018.10


                                        Gel with low F N              Gel with high F N







               Figure 2. Schematic representation of the level of normal force F N  for a HA gel. Impact on the shape and behavior of the gel for a product
               with a low F N  and a high F N

                                 Gel with low G’                              Gel with high G’

                            Dynamic       After the dynamic              Dynamic        After the dynamic
                          shearing forces  shearing forces             shearing forces   shearing forces



                 Initial shape  Deformation      No return to the   Initial shape  Deformation  Return to the
                                                  initial shape                                initial shape

                                 Gel with low E’                              Gel with high E’

                          Dynamic       After the dynamic               Dynamic      After the dynamic
                        compression    compression forces             compression    compression forces
                          forces                                         forces


                 Initial shape   Deformation     No return to the   Initial shape  Deformation  Return to the
                                                  initial shape                                initial shape
               Figure 3. Schematic representation of the level of elasticity G’ and E’ for a HA gel. Impact of the dynamic shearing and compression
               forces on the deformation and return to the initial shape of the gel

               product to resist to dynamic compression (i.e., behavior of the gel for recovering its shape after compression)
               [Figure 3]. Because a HA filler is subjected to very high levels of dynamic shear stress but also of dynamic
               compression stress at each moment of its in vivo life, when for instance, the patient speaks, smiles or eats,
               the G’ and E’ properties of the gel implant are key parameters to demonstrate its ability to respond to
               the mechanical constraints imposed by the dynamic facial expression. Thus, balanced G’ and E’ dynamic
               moduli confer a better capacity of the product to well respond to the muscular forces of the skin and to
               benefit of a better natural effect of the gel implanted in the tissues. Nevertheless, it is important to remember
               that this natural effect can be fully obtained only if the HA filler has an appropriate position and integration.

               Step 4 of HA fillers’ lifetime: degradation
               Over time, the HA fillers are degraded by the human body due to the actions of the free radicals, the
               hyaluronidases, the thermal hydrolysis and the mechanical stress . It is important to note that mechanical
                                                                      [15]
               stress should play a very important role in the loss of the clinical effect. Indeed, as the hyaluronic acid is little
               by little cut into smaller pieces by the endogenous actors of the skin, the perpetual action of the mechanical
               expression of the face fosters the loss of implant cohesivity and rheological properties, and especially the
               normal force F  (which enables to maintain the tissues projection) and the viscosity (which enables to resist
                            N
               to flow and spreading). The decrease over time of these key implant properties of the gel is fundamental to
               understand and explain the progressive disappearance of their clinical efficacy.

               Summary
               Following the discussion above, the Table 3 summarizes the key rheological properties for a HA filler, all
               along its clinical lifetime, from tissue integration to product degradation.
   16   17   18   19   20   21   22   23   24   25   26